Skip to main content
SpringerLink
Log in

Beta blockers and glucose metabolism in chronic heart failure: Friend or foe?

  • EDITORIAL
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Black JW, Duncan WA, Shanks RG (1965) Comparison of some properties of pronethanol and propranolol. Br J Pharmacol Chemother 25:577–591

    PubMed  CAS  Google Scholar 

  2. Bangalore S, Meserli FH, Kostis JB, Pepine CJ (2007) Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 50:563–572

    Article  PubMed  CAS  Google Scholar 

  3. Reil JC, Böhm M (2007) The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 96:585–592

    Article  PubMed  Google Scholar 

  4. Böhm M, Werner N, Kindermann M (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clin Res Cardiol 95(Suppl):36–54

    Article  PubMed  Google Scholar 

  5. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin L (1975) Effects of chronic beta-adrenergic blockade in congestive cardiomyopathy. Br Heart J 37:1022–1036

    Article  PubMed  CAS  Google Scholar 

  6. Swedberg K, Cleland J, Dargie H et al (2005) Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). Eur Heart J 26:1115–1140

    Article  PubMed  Google Scholar 

  7. Drechsler K, Dietz R, Klein H, Wollert KC, Storp D, Molling J, Zeymer U, Niebauer J (2005) Euro heart failure survey. Medical treatment not in line with current guidelines. Z Kardiol 94:510–515

    Article  PubMed  CAS  Google Scholar 

  8. Reibis R, Dovifat C, Dissmann R, Ehrlich B, Schulz S, Stolze K, Wegscheider K, Völler H (2006) Implementation of evidence-based therapy in patients with systolic heart failure from 1998–2000. Clin Res Cardiol 95:154–161

    Article  PubMed  CAS  Google Scholar 

  9. Taubert G, Bergmeier C, Andresen H, Senges J, Potratz J (2001) Clinical profile and management of heart failure: rural community hospital vs metropolitan heart center. Eur J Heart Failure 3:611–617

    Article  CAS  Google Scholar 

  10. Ko DT, Hebert PR, Coffey CS et al (2004) Adverse effects of _-blocker therapy for patients with heart failure. Arch Intern Med 164:1389–1394

    Article  PubMed  CAS  Google Scholar 

  11. Lainščak M, Cleland JGF, Lenzen MJ, Follath F, Komajda M, Swedberg K (2007) International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the Euro Heart Failure survey. Eur J Heart Fail 9:292–299

    Article  PubMed  Google Scholar 

  12. Lainščak M, Cleland JGF, Lenzen MJ, Keber I, Goode K, Follath F, Komajda M, Swedberg K (2007) Nonpharmacological measures and drug compliance in patients with heart failure: data from the Euro Heart Failure survey. Am J Cardiol 99(Suppl):31D–37D

    PubMed  Google Scholar 

  13. Paolisso G, De Riu S, Marrazzo G, Verza M, Varrichio M, D'Onofrio F (1991) Insulin resistence and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 40:972–977

    Article  PubMed  CAS  Google Scholar 

  14. Doehner W, Rauchhaus M, Ponikowski P et al (2005) Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46:1019–1026

    Article  PubMed  CAS  Google Scholar 

  15. Ferrua S, Bobbio M, Catalano E, Grassi G, Massobrio N, Pinach S, Rossi C, Veglio M, Trevi GP (2005) Does Carvedilol ipair insulin sensitivity in heart failure patients without diabetes? J Card Fail 11:590–594

    Article  PubMed  CAS  Google Scholar 

  16. Basat O, Ucak S, Seber S, Oztekin E, Altuntas Y (2006) After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol 95:99–104

    Article  PubMed  Google Scholar 

  17. Bakris GL, Fonseca V, Katholi RE et al (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. J Am Med Assoc 292:2227–2236

    Article  CAS  Google Scholar 

  18. Kovacic D, Marinsek M, Gobec L, Lainscak M, Podbregar M (2008) Effects of selective and non-selective β-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol (in press)

  19. Swan JW, Walton C, Godsland IF (1994) Assessment of insulin sensitivity in man: a comparison of minimal model and euglycaemic clamp derived measures in health and heart failure. Clinical Science 86:317–322

    PubMed  CAS  Google Scholar 

  20. Doehner W, Anker SD, Godsland IF (2005) Optimizing insulin sensitivity assessment using the minimal model in chronic heart failure. Horm Metab Res 37:106–110

    Article  PubMed  CAS  Google Scholar 

  21. Doehner W, Rauchhaus M, Godsland IF, Egerer K, Niebauer J, Sharma R, Cicoira M, Florea VG, Coats AJS, Anker SD (2002) Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine and TNF-alpha. Int J Cardiol 83:73–81

    Article  PubMed  Google Scholar 

  22. Flather MD, Shibata MS, Coats AJS et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225

    Article  PubMed  CAS  Google Scholar 

  23. Lainscak M, Keber I, Anker SD (2006) Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 106:319–322

    Article  PubMed  Google Scholar 

  24. Anker SD, Negassa A, Coats AJS et al (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin- converting-enzyme inhibitors: an observational study. Lancet 361:1077–1083

    Article  PubMed  CAS  Google Scholar 

  25. Springer J, Filippatos G, Akashi YJ, Anker SD (2006) Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 21:229–233

    Article  PubMed  Google Scholar 

  26. Podbregar M, Voga G (2002) Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail 8: 369–378

    Article  PubMed  CAS  Google Scholar 

  27. Doehner W (2006) Xanthine oxidase inhibitors and insulin sensitizers. In: Hofbauer, Anker, Inui, Nicholson (eds) Pharmacotherapy of Cachexia, CRC Press, pp 451–472

  28. Doehner W, Bunck AC, Rauchhaus M, von Haehling S, Brunkhorst FM, Cicoira M, Tschope C, Ponikowski P, Claus RA, Anker SD (2007) Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 28:821–828

    Article  PubMed  CAS  Google Scholar 

  29. von Haehling S, Doehner W, Anker SD (2007) Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73:298–309

    Article  PubMed  CAS  Google Scholar 

  30. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO (2006) Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 95(3):136–147

    Article  PubMed  CAS  Google Scholar 

  31. Lainscak M, Doehner W, Anker SD (2007) Metabolic disturbances in chronic heart failure: a case for the "macho" approach with testosterone?! Eur J Heart Fail 9:2–3

    Article  PubMed  CAS  Google Scholar 

  32. van der Haarst P, Voors AA, van Gilst WH, Böhm M, van Veldhuisen DJ (2007) Statins in the treatment of chronic heart failure: a systematic review. PLOS Med 3:e333

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Applied Cachexia Research, Department of Cardiology Campus Virchow Clinic, Charité Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353, Berlin, Germany

    Wolfram Doehner MD, PhD &  Stefan D. Anker MD, PhD

Authors
  1. Wolfram Doehner MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan D. Anker MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doehner, W., Anker, S.D. Beta blockers and glucose metabolism in chronic heart failure: Friend or foe?. Clin Res Cardiol 97, 21–23 (2008). https://doi.org/10.1007/s00392-008-0609-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-008-0609-1

Keywords

Search

Navigation